Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Series A generates impressive $104mm for Adaptimmune
27 Sep 2017
Adaptimmune Ltd. (developing T-cell therapies for cancer and infectious diseases) closed an oversubscribed Series A financing of $104mm. New Enterprise Associates led and was joined by other first-time backers OrbiMed Advisors, Wellington Management Co., Fidelity Biosciences, Foresite Capital Management, Ridgeback Capital Management, Novo AS, QVT, Rock Springs Capital, venBio Select, and Merlin Nexus, along with returning investors including the University of Oxford and others.
Gene Therapy, Cell Therapy
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?